XML 52 R17.htm IDEA: XBRL DOCUMENT v3.20.1
Segments of Business and Geographic Areas
 3 Months Ended
Mar. 29, 2020
Segment Reporting [Abstract]  
Segments of Business and Geographic Areas SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS

SALES BY SEGMENT OF BUSINESS
 
 
Fiscal First Quarter Ended
(Dollars in Millions)
 
March 29,
2020
 
March 31,
2019
 
Percent
Change
 
 
 
 
 
 
 
Consumer Health*
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
     U.S.
 
$
92

 
87

 
6.7
 %
     International
 
269

 
307

 
(12.4
)
     Worldwide
 
361

 
394

 
(8.2
)
Skin Health/Beauty
 
 
 
 
 
 
     U.S.
 
659

 
588

 
12.1

     International
 
458

 
502

 
(8.8
)
     Worldwide
 
1,117

 
1,090

 
2.5

Oral Care
 
 
 
 
 
 
     U.S.
 
176

 
151

 
16.2

     International
 
219

 
216

 
1.5

     Worldwide
 
395

 
367

 
7.6

OTC
 
 
 
 
 
 
     U.S.
 
689

 
507

 
35.9

     International
 
659

 
580

 
13.7

     Worldwide
 
1,348

 
1,087

 
24.1

Women's Health
 
 
 
 
 
 
     U.S.
 
4

 
3

 
32.0

     International
 
228

 
222

 
2.5

     Worldwide
 
232

 
225

 
2.9

Wound Care/Other
 
 
 
 
 
 
     U.S.
 
119

 
102

 
17.0

     International
 
52

 
53

 
(1.2
)
     Worldwide
 
171

 
155

 
10.7

TOTAL Consumer Health
 
 
 
 
 
 
     U.S.
 
1,740

 
1,438

 
21.0

     International
 
1,885

 
1,880

 
0.3

     Worldwide
 
3,625

 
3,318

 
9.2

* Previously referred to as Consumer
 
 
 
 
 
 
 
 
 
 
 
 
 

PHARMACEUTICAL
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
     U.S.
 
2,410

 
2,163

 
11.4

     International
 
1,228

 
1,088

 
12.8

     Worldwide
 
3,638

 
3,251

 
11.9

     REMICADE®
 
 
 
 
 
 
     U.S.
 
625

 
774

 
(19.3
)
     U.S. Exports
 
110

 
76

 
44.3

     International
 
256

 
252

 
1.5

     Worldwide
 
990

 
1,102

 
(10.2
)
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
     U.S.
 
272

 
263

 
3.4

     International
 
258

 
261

 
(1.2
)
     Worldwide
 
529

 
524

 
1.1

     STELARA®
 
 
 
 
 
 
     U.S.
 
1,217

 
882

 
37.9

     International
 
603

 
523

 
15.2

     Worldwide
 
1,819

 
1,405

 
29.5

     TREMFYA®
 
 
 
 
 
 
     U.S.
 
187

 
168

 
11.5
     International
 
109

 
49

 
*
     Worldwide
 
296

 
217

 
36.4
     OTHER IMMUNOLOGY
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—
     International
 
3

 
3

 
(6.9)
     Worldwide
 
3

 
3

 
(6.9)
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
     U.S.
 
436

 
357

 
22.3

     International
 
483

 
489

 
(1.2
)
     Worldwide
 
920

 
846

 
8.7

     EDURANT® / rilpivirine
 
 
 
 
 
 
     U.S.
 
12

 
12

 
0.6

     International
 
212

 
199

 
6.4

     Worldwide
 
224

 
211

 
6.1

     PREZISTA® / PREZCOBIX® /                                                REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
     U.S.
 
396

 
315

 
25.5

     International
 
184

 
208

 
(11.6
)
     Worldwide
 
579

 
523

 
10.8

     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
     U.S.
 
29

 
30

 
(3.4
)
     International
 
87

 
82

 
6.7

     Worldwide
 
116

 
112

 
4.0

 
 
 
 
 
 
 

Neuroscience
 
 
 
 
 
 
     U.S.
 
748

 
723

 
3.3

     International
 
910

 
905

 
0.5

     Worldwide
 
1,658

 
1,629

 
1.8

     CONCERTA® / methylphenidate
 
 
 
 
 
 
     U.S.
 
52

 
97

 
(46.1
)
     International
 
118

 
116

 
1.5

     Worldwide
 
171

 
214

 
(20.1
)
     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
 
 
 
 
 
 
     U.S.
 
544

 
483

 
12.6

     International
 
339

 
307

 
10.3

     Worldwide
 
883

 
790

 
11.7

     RISPERDAL CONSTA®
 
 
 
 
 
 
     U.S.
 
76

 
77

 
(0.3
)
     International
 
94

 
102

 
(8.7
)
     Worldwide
 
170

 
179

 
(5.1
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
     U.S.
 
75

 
66

 
12.5

     International
 
360

 
379

 
(5.1
)
     Worldwide
 
435

 
446

 
(2.5
)
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
     U.S.
 
1,175

 
962

 
22.1

     International
 
1,839

 
1,556

 
18.2

     Worldwide
 
3,013

 
2,518

 
19.7

     DARZALEX®
 
 
 
 
 
 
     U.S.
 
463

 
352

 
31.8

     International
 
474

 
277

 
70.9

     Worldwide
 
937

 
629

 
49.0

     ERLEADA® 
 
 
 
 
 
 
     U.S.
 
119

 
58

 
 *
     International
 
24

 
3

 
 *
     Worldwide
 
143

 
61

 
 *
     IMBRUVICA®
 
 
 
 
 
 
     U.S.
 
432

 
349

 
23.9

     International
 
599

 
435

 
37.8

     Worldwide
 
1,031

 
784

 
31.6

     VELCADE®
 
 
 
 
 
 
     U.S.
 
—

 
—

 
—
     International
 
108

 
263

 
(59.0
)
     Worldwide
 
108

 
263

 
(59.0
)
     ZYTIGA® / abiraterone acetate
 
 
 
 
 
 
     U.S.
 
139

 
185

 
(25.2
)
     International
 
552

 
494

 
11.7

     Worldwide
 
690

 
679

 
1.6

 
 
 
 
 
 
 

     OTHER ONCOLOGY
 
 
 
 
 
 
     U.S.
 
22

 
18

 
20.1
     International
 
82

 
84

 
(2.7)
     Worldwide
 
104

 
102

 
1.3
 
 
 
 
 
 
 
Pulmonary Hypertension
 
 
 
 
 
 
     U.S.
 
486

 
430

 
13.0
     International
 
260

 
226

 
14.9
     Worldwide
 
745

 
656

 
13.7
     OPSUMIT®
 
 
 
 
 
 
     U.S.
 
229

 
172

 
33.0
     International
 
160

 
133

 
20.2
     Worldwide
 
389

 
306

 
27.4
     UPTRAVI®
 
 
 
 
 
 
     U.S.
 
212

 
176

 
20.7
     International
 
38

 
22

 
70.2
     Worldwide
 
250

 
198

 
26.2
     OTHER PULMONARY HYPERTENSION
 
 
 
 
 
 
     U.S.
 
44

 
82

 
(45.9)
     International
 
62

 
71

 
(12.4)
     Worldwide
 
106

 
152

 
(30.4)
 
 
 
 
 
 
 
Cardiovascular / Metabolism / Other
 
 
 
 
 
 
     U.S.
 
806

 
947

 
(14.9
)
     International
 
354

 
398

 
(11.0
)
     Worldwide
 
1,160

 
1,345

 
(13.8
)
     XARELTO®
 
 
 
 
 
 
     U.S.
 
527

 
542

 
(2.7
)
     International
 
—

 
—

 
—
     Worldwide
 
527

 
542

 
(2.7
)
     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
     U.S.
 
117

 
154

 
(23.6
)
     International
 
58

 
49

 
18.6

     Worldwide
 
175

 
202

 
(13.5
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
     U.S.
 
76

 
148

 
(48.5
)
     International
 
79

 
78

 
0.4

     Worldwide
 
155

 
226

 
(31.6
)
     OTHER
 
 
 
 
 
 
     U.S.
 
85

 
104

 
(18.0
)
     International
 
217

 
271

 
(19.7
)
     Worldwide
 
302

 
374

 
(19.2
)
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
     U.S.
 
6,061

 
5,582

 
8.6

     International
 
5,073

 
4,662

 
8.8

     Worldwide
 
11,134

 
10,244

 
8.7

 
 
 
 
 
 
 

MEDICAL DEVICES
 
 
 
 
 
 
Interventional Solutions
 
 
 
 
 
 
     U.S.
 
365

 
343

 
6.6

     International
 
362

 
389

 
(6.9
)
     Worldwide
 
727

 
732

 
(0.6
)
Orthopaedics
 
 
 
 
 
 
     U.S.
 
1,250

 
1,318

 
(5.2
)
     International
 
788

 
885

 
(11.0
)
     Worldwide
 
2,038

 
2,204

 
(7.5
)
     HIPS
 
 
 
 
 
 
     U.S.
 
206

 
213

 
(3.6
)
     International
 
132

 
148

 
(11.2
)
     Worldwide
 
337

 
361

 
(6.7
)
     KNEES
 
 
 
 
 
 
     U.S.
 
214

 
223

 
(4.2
)
     International
 
130

 
146

 
(11.4
)
     Worldwide
 
343

 
369

 
(7.0
)
     TRAUMA
 
 
 
 
 
 
     U.S.
 
407

 
417

 
(2.3
)
     International
 
247

 
268

 
(8.0
)
     Worldwide
 
654

 
685

 
(4.5
)
     SPINE, SPORTS & OTHER
 
 
 
 
 
 
     U.S.
 
423

 
465

 
(8.9
)
     International
 
280

 
323

 
(13.3
)
     Worldwide
 
703

 
788

 
(10.7
)
Surgery
 
 
 
 
 
 
     U.S.
 
844

 
1,001

 
(15.7
)
     International
 
1,257

 
1,394

 
(9.8
)
     Worldwide
 
2,100

 
2,395

 
(12.3
)
     ADVANCED
 
 
 
 
 
 
     U.S.
 
381

 
404

 
(5.7
)
     International
 
567

 
576

 
(1.6
)
     Worldwide
 
948

 
980

 
(3.3
)
     GENERAL
 
 
 
 
 
 
     U.S.
 
463

 
597

 
(22.5
)
     International
 
690

 
818

 
(15.7
)
     Worldwide
 
1,153

 
1,414

 
(18.5
)
Vision
 
 
 
 
 
 
     U.S.
 
439

 
446

 
(1.6
)
     International
 
628

 
682

 
(8.0
)
     Worldwide
 
1,067

 
1,129

 
(5.5
)
     CONTACT LENSES / OTHER
 
 
 
 
 
 
     U.S.
 
346

 
321

 
7.7

     International
 
467

 
502

 
(7.0
)
     Worldwide
 
814

 
824

 
(1.3
)
     SURGICAL
 
 
 
 
 
 
     U.S.
 
93

 
125

 
(25.5
)

     International
 
160

 
180

 
(11.0
)
     Worldwide
 
253

 
305

 
(16.9
)
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
     U.S.
 
2,898

 
3,109

 
(6.8
)
     International
 
3,034

 
3,350

 
(9.4
)
     Worldwide
 
5,932

 
6,459

 
(8.2
)
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
     U.S.
 
10,699

 
10,129

 
5.6

     International
 
9,992

 
9,892

 
1.0

     Worldwide
 
$
20,691

 
20,021

 
3.3
 %

*Percentage greater than 100% or not meaningful

EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 
 
Fiscal First Quarter Ended
(Dollars in Millions)
 
March 29,
2020
 
March 31,
2019
 
Percent
Change
Consumer Health (1)
 
$
770

 
741

 
3.9
%
Pharmaceutical(2)
 
3,834

 
2,331

 
64.5

Medical Devices(3)
 
2,025

 
1,497

 
35.3

Segment earnings before provision for taxes
 
6,629

 
4,569

 
45.1

Less: Expense not allocated to segments (4)
 
120

 
147

 
 

Worldwide income before tax
 
$
6,509

 
4,422

 
47.2
%

(1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (DR. CI: LABO) in the fiscal first quarter of 2019. Includes amortization expense of $0.1 billion in both the fiscal first quarters of 2020 and 2019, respectively.
  
(2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset in the fiscal first quarter of 2019. Includes litigation expense of $0.1 billion and $0.3 billion in the fiscal first quarter of 2020 and 2019, respectively. Includes an unrealized loss on securities of $0.3 billion in the fiscal first quarter of 2020 and an unrealized gain on securities of $0.1 billion in the fiscal first quarter of 2019. Additionally, the fiscal first quarter of 2019 includes a research and development expense of $0.3 billion for an upfront payment related to argenx. Includes amortization expense of $0.8 billion in both the fiscal first quarters of 2020 and 2019.
(3) Includes a contingent consideration reversal of $1.0 billion in the fiscal first quarter of 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. Includes litigation expense of $0.1 billion in the fiscal first quarter of 2019. Includes a restructuring related charge of $0.1 billion and amortization expense of $0.2 billion in both the fiscal first quarters of 2020 and 2019.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
SALES BY GEOGRAPHIC AREA
 
 
Fiscal First Quarter Ended
(Dollars in Millions)
 
March 29, 2020
 
March 31, 2019
 
Percent
Change
United States
 
$
10,699

 
10,129

 
5.6
 %
Europe
 
4,827

 
4,609

 
4.7

Western Hemisphere, excluding U.S.
 
1,502

 
1,503

 
(0.1
)
Asia-Pacific, Africa
 
3,663

 
3,780

 
(3.1
)
Total
 
$
20,691

 
20,021

 
3.3
 %